BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980-988. [PMID: 24368224 DOI: 10.1053/j.gastro.2013.12.028] [Cited by in Crossref: 118] [Cited by in F6Publishing: 108] [Article Influence: 13.1] [Reference Citation Analysis]
Number Citing Articles
1 Kim JH, Lee JS. Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B? Korean J Intern Med 2015;30:23-6. [PMID: 25589830 DOI: 10.3904/kjim.2015.30.1.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Martin P, Lau DT, Nguyen MH, Janssen HL, Dieterich DT, Peters MG, Jacobson IM. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 2015;13:2071-2087.e16. [DOI: 10.1016/j.cgh.2015.07.007] [Cited by in Crossref: 73] [Cited by in F6Publishing: 60] [Article Influence: 10.4] [Reference Citation Analysis]
3 Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Review of Anti-infective Therapy 2018;16:153-61. [DOI: 10.1080/14787210.2018.1428561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
4 Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH;  American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261-283. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1159] [Cited by in F6Publishing: 1064] [Article Influence: 165.6] [Reference Citation Analysis]
5 Park CH, Jung SW, Shin JW, Bae MA, Lee YI, Park YT, Chung HS, Park NH. Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. Clin Mol Hepatol 2016;22:152-9. [PMID: 27044766 DOI: 10.3350/cmh.2016.22.1.152] [Reference Citation Analysis]
6 Nishijima T, Hayashida T, Kurosawa T, Tanaka N, Oka S, Gatanaga H. Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study. PLoS One 2015;10:e0141931. [PMID: 26535588 DOI: 10.1371/journal.pone.0141931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Lim Y, Lee YS, Gwak G, Byun KS, Kim YJ, Choi J, An J, Lee HC, Yoo BC, Kwon SY. Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. Hepatology 2017;66:772-83. [DOI: 10.1002/hep.29187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
8 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 21.3] [Reference Citation Analysis]
9 Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open 2018;2:288-94. [PMID: 30619939 DOI: 10.1002/jgh3.12086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Soriano V, de Mendoza C, Peña JM, Barreiro P. Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. Expert Opin Pharmacother 2015;16:179-86. [PMID: 25529507 DOI: 10.1517/14656566.2015.973852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, Mete AO, Golbol A, Nazik S, Kömür S, Merve Oren M, Yildiz Y, Demir Y, Ayhan M, Tasova Y, Bayındır Y, Dal T, Celen MK. Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118721] [Reference Citation Analysis]
13 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/AAC.03845-14] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
14 Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
15 De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018;153:2-11. [PMID: 29225131 DOI: 10.1016/j.bcp.2017.11.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
16 Liu Y, Miller MD, Kitrinos KM. Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. Antiviral Res 2017;139:25-31. [PMID: 28017761 DOI: 10.1016/j.antiviral.2016.12.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
17 Cho EY, Yim HJ, Jung YK, Suh SJ, Seo YS, Kim JH, Kim HS, Lee SH, Ahn SH, Lee JI, Jeong SH, Kim JW, Lee JW, Kim IH, Kim HS, Park SJ, Lee JM, Hwang SG; Antiviral Resistance Study Group. Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study. Gut Liver 2017;11:129-35. [PMID: 27538443 DOI: 10.5009/gnl15597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
18 Lee YB, Lee JH, Lee DH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ, Cho Y. Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains. Antimicrob Agents Chemother. 2014;58:6710-6716. [PMID: 25155601 DOI: 10.1128/aac.03845-14aac.03845-14] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020;52:500-12. [PMID: 32583915 DOI: 10.1111/apt.15901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Fung S, Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Gane E, Jacobson IM, Yee LJ, Dinh P. Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml). Liver Int. 2015;35:422-428. [PMID: 25277773 DOI: 10.1111/liv.12694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
21 Song BC. Switch to tenofovir-based therapy or to continue adefovir-based therapy in CHB patients with suboptimal response to adefovir-based combination? Clin Mol Hepatol 2016;22:439-42. [PMID: 28081595 DOI: 10.3350/cmh.2016.0108] [Reference Citation Analysis]
22 Lim YS, Yoo BC, Byun KS, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. Gut. 2016;65:1042-1051. [PMID: 25800784 DOI: 10.1136/gutjnl-2014-308435] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 8.9] [Reference Citation Analysis]
23 Kim BG, Jung SW, Kim EH, Kim JH, Park JH, Sung SJ, Park BR, Kim M, Kim CJ, Lee BU, Park JH, Jeong ID, Bang S, Shin JW, Park NH. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir: Tenofovir in multidrug resistant hepatitis B. J Gastroenterol Hepatol 2015;30:1514-21. [DOI: 10.1111/jgh.12993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
24 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 21.8] [Reference Citation Analysis]
25 Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, Aguilar Schall R, Flaherty JF, Martins EB, Charuworn P, Kitrinos KM, Subramanian GM, Gane E, Marcellin P. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457-1464. [PMID: 25532501 DOI: 10.1007/s10620-014-3486-7] [Cited by in Crossref: 173] [Cited by in F6Publishing: 155] [Article Influence: 21.6] [Reference Citation Analysis]
26 Petersen J, Heyne R, Mauss S, Schlaak J, Schiffelholz W, Eisenbach C, Hartmann H, Wiese M, Boeker K, Loehr HF, John C, Leuschner M, Trautwein C, Felten G, Trein A, Krause W, Ruppert S, Warger T, Hueppe D. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Dig Dis Sci. 2016;61:3061-3071. [PMID: 26576555 DOI: 10.1007/s10620-015-3960-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
27 Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:196-206. [PMID: 28404092 DOI: 10.1016/s2468-1253(16)30107-8] [Cited by in Crossref: 218] [Cited by in F6Publishing: 75] [Article Influence: 36.3] [Reference Citation Analysis]
28 Zhang L, Zhang FK. Treatment of chronic hepatitis B with tenofovir. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4279-4287 [DOI: 10.11569/wcjd.v24.i31.4279] [Reference Citation Analysis]
29 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
30 Liu Y, Chang S, Martin R, Flaherty J, Mo H, Feierbach B. Characterization of Hepatitis B virus polymerase mutations A194T and CYEI and tenofovir disoproxil fumarate or tenofovir alafenamide resistance. J Viral Hepat 2021;28:30-9. [PMID: 32894807 DOI: 10.1111/jvh.13397] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Dejban P, Nikravangolsefid N, Chamanara M, Dehpour A, Rashidian A. The role of medicinal products in the treatment of inflammatory bowel diseases (IBD) through inhibition of TLR4/NF-kappaB pathway. Phytother Res 2021;35:835-45. [PMID: 32929778 DOI: 10.1002/ptr.6866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Agarwal K, Brunetto M, Seto WK, Lim Y, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang W, Bae H, Sharma M, Janssen HL, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HL. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology 2018;68:672-81. [DOI: 10.1016/j.jhep.2017.11.039] [Cited by in Crossref: 137] [Cited by in F6Publishing: 122] [Article Influence: 34.3] [Reference Citation Analysis]
33 Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019;71:35-44. [PMID: 30876946 DOI: 10.1016/j.jhep.2019.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
34 Liu K, Choi J, Le A, Yip TC, Wong VW, Chan SL, Chan HL, Nguyen MH, Lim YS, Wong GL. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther 2019;50:1037-48. [PMID: 31524304 DOI: 10.1111/apt.15499] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 6.7] [Reference Citation Analysis]
35 Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother 2018;62:e01064-18. [PMID: 30038044 DOI: 10.1128/AAC.01064-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
36 Chen J, Zhao SS, Liu XX, Huang ZB, Huang Y. Comparison of the Efficacy of Tenofovir Versus Tenofovir plus Entecavir in the Treatment of Chronic Hepatitis B in Patients With Poor Efficacy of Entecavir: A Systematic Review and Meta-analysis. Clin Ther 2017;39:1870-80. [PMID: 28797777 DOI: 10.1016/j.clinthera.2017.07.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
37 Li Z, Liu J, Ju G, Yan K, Mao Y, Liu Q, Yang X, Zhang R, Qiu W. Pharmacokinetics and Bioequivalence Evaluation of 2 Formulations of Tenofovir Alafenamide. Clin Pharmacol Drug Dev 2021. [PMID: 34352149 DOI: 10.1002/cpdd.985] [Reference Citation Analysis]
38 Chen L, Wang X, Zhang Q, Gong J, Shen S, Yin W, Hu H. Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis. Gastroenterol Res Pract. 2016;2016:7214020. [PMID: 26880896 DOI: 10.1155/2016/7214020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
39 Li J, Zhang D, Zhang X. The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. Infect Drug Resist 2021;14:1013-7. [PMID: 33758517 DOI: 10.2147/IDR.S295060] [Reference Citation Analysis]
40 Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, Cho SW, Kim SS. Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients. Clin Mol Hepatol 2015;21:131-40. [PMID: 26157750 DOI: 10.3350/cmh.2015.21.2.131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Beloukas A, Geretti AM. Hepatitis B Virus Drug Resistance. In: Mayers DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial Drug Resistance. Cham: Springer International Publishing; 2017. pp. 1227-42. [DOI: 10.1007/978-3-319-47266-9_26] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
42 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pan CQ, Chan S, Trinh H, Yao A, Bae H, Lou L. Similar efficacy and safety of tenofovir in Asians and non-Asians with chronic hepatitis B. World J Gastroenterol 2015; 21(18): 5524-5531 [PMID: 25987775 DOI: 10.3748/wjg.v21.i18.5524] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
44 Huang M, Jie Y, Lin G, Shi H, Li X, Li X, Wu Y, Chong Y. Long-Term Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleos(t)ide-Experienced Chronic Hepatitis B Patients. Clin Drug Investig 2016;36:471-8. [PMID: 26992717 DOI: 10.1007/s40261-016-0392-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
45 Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S, Gatanaga H. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS 2016;30:1563-71. [PMID: 26919734 DOI: 10.1097/QAD.0000000000001070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
46 Lim YS, Byun KS, Yoo BC, Kwon SY, Kim YJ, An J, Lee HC, Lee YS. Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. Gut. 2016;65:852-860. [PMID: 25596179 DOI: 10.1136/gutjnl-2014-308353] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
47 Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20. [PMID: 31480433 DOI: 10.3390/ijms20174270] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
48 Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, Gurel S, Caruntu FA, Flaherty JF, Massetto B. Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. J Hepatol. 2017;66:11-18. [PMID: 27545497 DOI: 10.1016/j.jhep.2016.08.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
49 Kim DY, Lee HW, Song JE, Kim BK, Kim SU, Kim DY, Ahn SH, Han KH, Park JY. Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance. J Med Virol 2018;90:497-502. [PMID: 29077211 DOI: 10.1002/jmv.24986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
50 Coppolino G, Simeoni M, Summaria C, Postorino MC, Rivoli L, Strazzulla A, Torti C, Fuiano G. The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 2015;28:393-402. [DOI: 10.1007/s40620-015-0214-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
51 Boyd A, Dezanet LNC, Lacombe K. Functional Cure of Hepatitis B Virus Infection in Individuals With HIV-Coinfection: A Literature Review. Viruses 2021;13:1341. [PMID: 34372547 DOI: 10.3390/v13071341] [Reference Citation Analysis]
52 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016;22:18-75. [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 19.2] [Reference Citation Analysis]
53 Rodríguez M, Pascasio JM, Fraga E, Fuentes J, Prieto M, Sánchez-Antolín G, Calleja JL, Molina E, García-Buey ML, Blanco MÁ, Salmerón J, Bonet ML, Pons JA, González JM, Casado MÁ, Jorquera F, the TENOSIMP-B Research Group. Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study. World J Gastroenterol 2017; 23(41): 7459-7469 [PMID: 29151700 DOI: 10.3748/wjg.v23.i41.7459] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
54 Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study. J Viral Hepat 2017;24:1089-97. [PMID: 28581644 DOI: 10.1111/jvh.12736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
55 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
56 Qian L, Fan H, Ju Y, Chen L, Li X, Ye X, Luo Y, Li C, Meng S. A peptide-based inhibitor of gp96 suppresses HBsAg expression and HBV replication by upregulation of p53. J Gen Virol 2019;100:1241-52. [PMID: 31204972 DOI: 10.1099/jgv.0.001289] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
57 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
58 Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, Oka S, Cheng A, Garner W, Fordyce M, Das M, McCallister S; GS-US-292-1249 Study Investigators. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016;73:294-8. [PMID: 27171740 DOI: 10.1097/QAI.0000000000001069] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 8.4] [Reference Citation Analysis]
59 Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E, Zhao S, Subramanian GM. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62:533-540. [PMID: 25450717 DOI: 10.1016/j.jhep.2014.10.035] [Cited by in Crossref: 101] [Cited by in F6Publishing: 101] [Article Influence: 12.6] [Reference Citation Analysis]
60 Xu B, Lin L, Xu G, Zhuang Y, Guo Q, Liu Y, Wang H, Zhou X, Wu S, Bao S, Cai W, Xie Q. Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2015;30:372-378. [PMID: 25167956 DOI: 10.1111/jgh.12718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
61 Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Oka S. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS 2014;28:1903-10. [PMID: 25259702 DOI: 10.1097/QAD.0000000000000347] [Cited by in Crossref: 50] [Cited by in F6Publishing: 25] [Article Influence: 7.1] [Reference Citation Analysis]
62 Lee S, Park JY, Kim do Y, Kim BK, Kim SU, Song K, Ku HJ, Han KH, Ahn SH. Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. J Med Virol. 2016;88:1027-1034. [PMID: 26538234 DOI: 10.1002/jmv.24427] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
63 Konerman MA, Lok AS. Interferon Treatment for Hepatitis B. Clin Liver Dis. 2016;20:645-665. [PMID: 27742005 DOI: 10.1016/j.cld.2016.06.002] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
64 Soriano V, Labarga P, de Mendoza C, Peña JM, Fernández-montero JV, Benítez L, Esposito I, Barreiro P. Emerging Challenges in Managing Hepatitis B in HIV Patients. Curr HIV/AIDS Rep 2015;12:344-52. [DOI: 10.1007/s11904-015-0275-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
65 Emery JS, Feld JJ. Treatment of hepatitis B virus with combination therapy now and in the future. Best Pract Res Clin Gastroenterol. 2017;31:347-355. [PMID: 28774417 DOI: 10.1016/j.bpg.2017.04.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
66 Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ. No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment. J Viral Hepat. 2017;24:68-74. [PMID: 27658343 DOI: 10.1111/jvh.12613] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 11.0] [Reference Citation Analysis]
67 Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. [Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B]. Korean J Gastroenterol 2015;65:35-42. [PMID: 25603852 DOI: 10.4166/kjg.2015.65.1.35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Petersen J. Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B? Journal of Hepatology 2015;62:505-7. [DOI: 10.1016/j.jhep.2014.12.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 de Fraga RS, Van Vaisberg V, Mendes LCA, Carrilho FJ, Ono SK. Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review. J Gastroenterol 2020;55:496-514. [PMID: 32185517 DOI: 10.1007/s00535-020-01680-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
70 Liu SK, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016;10:697-707. [DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
71 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
72 Corsa AC, Liu Y, Flaherty JF, Mitchell B, Fung SK, Gane E, Miller MD, Kitrinos KM. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol. 2014;12:2106-2112.e1. [PMID: 24929235 DOI: 10.1016/j.cgh.2014.05.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
73 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
74 Huang YS, Chang SY, Sheng WH, Sun HY, Lee KY, Chuang YC, Su YC, Liu WC, Hung CC, Chang SC. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection. PLoS One 2016;11:e0169228. [PMID: 28033344 DOI: 10.1371/journal.pone.0169228] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
75 Yuen M, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK, Lee J, Park NH, Kweon Y, Sohn JH, Lee J, Kim J, Lai C, Han K. Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. Journal of Hepatology 2015;62:526-32. [DOI: 10.1016/j.jhep.2014.10.026] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
76 Min IS, Lee CH, Shin IS, Lee NE, Son HS, Kim SB, Seo SY, Kim SH, Kim SW, Lee SO, Lee ST, Kim IH. Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate. Gut Liver 2019;13:93-103. [PMID: 30400723 DOI: 10.5009/gnl18183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
77 Zhang X, Li M, Xi H, Zhang R, Chen J, Zhang Y, Xu X. Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing. Oncotarget. 2016;7:70264-70275. [PMID: 27602500 DOI: 10.18632/oncotarget.11840] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
78 Yamashige D, Hosaka T, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs. J Gastroenterol 2021;56:1008-21. [PMID: 34596753 DOI: 10.1007/s00535-021-01826-8] [Reference Citation Analysis]
79 Park JY, Kim CW, Bae SH, Jung KS, Kim HY, Yoon SK, Han KH, Ahn SH. Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. Liver Int 2016;36:1108-15. [PMID: 26781724 DOI: 10.1111/liv.13059] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
80 Cho HJ, Kim SS, Shin SJ, Yoo BM, Cho SW, Cheong JY. Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance. J Med Virol. 2015;87:1532-1538. [PMID: 25940352 DOI: 10.1002/jmv.24201] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
81 Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World J Hepatol 2017; 9(5): 227-241 [PMID: 28261380 DOI: 10.4254/wjh.v9.i5.227] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
82 Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol 2017;11:999-1008. [PMID: 28965428 DOI: 10.1080/17474124.2017.1386554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
83 De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016;29:695-747. [PMID: 27281742 DOI: 10.1128/cmr.00102-15] [Cited by in Crossref: 592] [Cited by in F6Publishing: 276] [Article Influence: 98.7] [Reference Citation Analysis]
84 Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients. World J Gastroenterol 2015; 21(9): 2746-2753 [PMID: 25759545 DOI: 10.3748/wjg.v21.i9.2746] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
85 Tsai WC, Hsu WT, Liu WD, Sun HY, Chuang YC, Huang YS, Cheng A, Lin KY, Huang YC, Chen GJ, Huang SH, Sheng WH, Hsieh SM, Hung CC, Chang SC. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection. Liver Int 2019;39:1408-17. [PMID: 30712284 DOI: 10.1111/liv.14059] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
86 Kim DY, Park JY. Step-down strategy in antiviral resistant chronic hepatitis B patients who achieved viral suppression with rescue combination therapy. Future Virology 2018;13:711-7. [DOI: 10.2217/fvl-2018-0078] [Reference Citation Analysis]
87 Lee J, Kim GA, Kim HJ, Cho S, Ko MJ, Lim YS. Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. J Viral Hepat 2021;28:1150-9. [PMID: 33934466 DOI: 10.1111/jvh.13530] [Reference Citation Analysis]
88 Liu Y, Chang S, Hsieh D, Burdette D, Martin R, Mo H, Feierbach B. Generation of an HBV core phenotyping assay for evaluating HBV capsid compounds. J Virol Methods 2021;292:114117. [PMID: 33657432 DOI: 10.1016/j.jviromet.2021.114117] [Reference Citation Analysis]
89 Li Y, Xie J, Han Y, Wang H, Zhu T, Wang N, Lv W, Guo F, Qiu Z, Li Y, Du S, Song X, Thio CL, Li T. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL. J Acquir Immune Defic Syndr 2016;72:39-45. [PMID: 26745828 DOI: 10.1097/QAI.0000000000000927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
90 Ahn HJ, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK. Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea. PLoS One 2017;12:e0170362. [PMID: 28114428 DOI: 10.1371/journal.pone.0170362] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
91 Fasano M, Maggi P, Leone A, Volpe A, Fiore JR, Angarano G, Santantonio TA. Long-term efficacy and safety of switching from lamivudine+adefovir to tenofovir disoproxil fumarate in virologically suppressed patients. Dig Liver Dis 2017;49:530-4. [PMID: 28179096 DOI: 10.1016/j.dld.2017.01.140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, Miller MD, Kitrinos KM. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol 2014;86:1473-81. [PMID: 24861361 DOI: 10.1002/jmv.23982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
93 Lee YB, Jung EU, Kim BH, Lee JH, Cho H, Ahn H, Choi WM, Cho YY, Lee M, Yoo JJ. Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother. 2015;59:972-978. [PMID: 25421484 DOI: 10.1128/AAC.04454-14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
94 Wang HM, Hung CH, Lee CM, Lu SN, Wang JH, Yen YH, Kee KM, Chang KC, Tseng PL, Hu TH, Chen CH. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients. J Gastroenterol Hepatol 2016;31:1307-14. [PMID: 26758501 DOI: 10.1111/jgh.13294] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
95 Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5. [PMID: 25833942 DOI: 10.1101/cshperspect.a021501] [Cited by in Crossref: 92] [Cited by in F6Publishing: 91] [Article Influence: 13.1] [Reference Citation Analysis]
96 Ataei B, Khodadoostan M, Pouria B, Adibi P. Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series. J Res Pharm Pract 2016;5:166-70. [PMID: 27512706 DOI: 10.4103/2279-042X.185714] [Reference Citation Analysis]
97 Wang HL, Lu X, Yang X, Ning Q. Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2015; Nov 24. [Epub ahead of print]. [PMID: 26621535 DOI: 10.1016/j.clinre.2015.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
98 Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol 2020;5:441-53. [PMID: 32087795 DOI: 10.1016/S2468-1253(19)30421-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 15.5] [Reference Citation Analysis]
99 Lee S, Ahn SH, Jung KS, Kim DY, Kim BK, Kim SU, Baatarkhuu O, Ku HJ, Han K, Park JY. Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance. J Viral Hepat 2017;24:141-7. [DOI: 10.1111/jvh.12623] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
100 Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K;  GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185-195. [PMID: 28404091 DOI: 10.1016/s2468-1253(16)30024-3] [Cited by in Crossref: 196] [Cited by in F6Publishing: 71] [Article Influence: 32.7] [Reference Citation Analysis]
101 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
102 Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39:1868-1875. [PMID: 31136052 DOI: 10.1111/liv.14155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
103 Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12:e0184550. [PMID: 28898281 DOI: 10.1371/journal.pone.0184550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
104 Cui G, Xu X, Diao H. Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B. Sci Rep 2015;5:11854. [PMID: 26165204 DOI: 10.1038/srep11854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
105 Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, Kallis YN, Marley RT, Kooner P, Foster GR. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211:374-382. [PMID: 25156561 DOI: 10.1093/infdis/jiu471] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
106 Lee HJ, Kim SJ, Kweon YO, Park SY, Heo J, Woo HY, Hwang JS, Chung WJ, Lee CH, Kim BS, Suh JI, Tak WY, Jang BK. Evaluating the efficacy of switching from lamivudine plus adefovir to tenofovir disoproxil fumarate monotherapy in lamivudine-resistant stable hepatitis B patients. PLoS One 2018;13:e0190581. [PMID: 29329305 DOI: 10.1371/journal.pone.0190581] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
107 Yim HJ, Kim IH, Suh SJ, Jung YK, Kim JH, Seo YS, Yeon JE, Kim CW, Kwon SY, Park SH, Lee MS, Um SH, Byun KS. Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: a randomized controlled trial. J Viral Hepat. 2018;25:1321-1330. [PMID: 29772084 DOI: 10.1111/jvh.12934] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
108 Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection: 2019 update. Hepatol Res 2020;50:892-923. [PMID: 32343469 DOI: 10.1111/hepr.13504] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
109 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
110 Nishijima T, Mutoh Y, Kawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, Oka S; ACC Study Team. Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued. AIDS 2018;32:179-88. [PMID: 29028660 DOI: 10.1097/QAD.0000000000001667] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
111 Kozielewicz D, Halota W, Wietlicka-Piszcz M. Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment. Hepatol Int 2016;10:302-9. [PMID: 26612013 DOI: 10.1007/s12072-015-9681-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]